Related Experiment Video
Updated: Jun 25, 2026

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
Published on: July 24, 2013
The association between dehydroepiandosterone and frailty in older men and women
M Voznesensky1, S Walsh, D Dauser
1University of Connecticut Health Center, Farmington, CT 06030, USA.
Objectives:
to evaluate the association between dehydroepiandosterone (DHEA) and physical frailty in older adults.
Design:
cross-sectional analysis of baseline information from three separate studies in healthy older men, women and residents of assisted living.
Setting:
academic health centre in greater Hartford, CT, USA.
Participants:
eight hundred and ninety-eight adults residing in the community or assisted living facility.
Measurements:
participants had measurement of frailty (weight loss, grip strength, sense of exhaustion, walking speed and physical activity) and serum DHEAS levels.
Results:
overall, 6% of the individuals in the study were classified as frail, 58% intermediate frail and 35% were not frail. In the bivariate analysis, there were differences between categories of frailty across age, gender and by DHEAS levels. In an ordinal logistic regression model, with frailty as a dependent measure, we found that age, DHEAS and interactions of age and BMI and DHEAS and BMI were predictive of more frailty characteristics.
Conclusion:
we found an association between frailty and DHEAS levels. Whether the association is due to similar conditions resulting in lower DHEA levels and more susceptibility to frailty or whether lower DHEA levels have an impact on increasing frailty cannot be addressed by cross-sectional analysis. Gender did not impact the association between DHEAS and frailty, but obesity (BMI > 30 kg/m(2)) attenuated the association between higher DHEA levels and lower frailty status.
Related Concept Videos
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Drug Dosing: Geriatric Patients
Pharmacodynamics in Geriatric Patients: Effects of Age
Menopause
The Effect of Aging on Tissues
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

